Compugen Ltd. · NASDAQ:CGEN

Compugen — Investor Presentation (May 2005)

29 slides from Compugen's investor presentation, May 2005

  1. Slide 1: Compugen: Pharma Discovery for the 21st Century

    Compugen: Pharma Discovery for the 21st Century May 2005

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words like "may," "expects," "believes," and "intends," and describe opinions about future events. These forward-looking

  3. Slide 3: Agenda

    Agenda • R&D Process • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Business Model

  4. Slide 4: R&D Process

    = R&D Process

  5. Slide 5: Probability Of Success (POS)

    Probability Of Success (POS) • POS: The chances a given discovery will result in a product • Our mission – To increase the probability of success of drug and diagnostic development by incorporating ideas and methods from mathematics, computer science, and physics into life science

  6. Slide 6: What We Do

    What We Do • Build technologies that address POS- critical components in the drug discovery process • Current major technologies: – Genomic infrastructure platforms – Discovery engines: therapeutic proteins and biomarkers

  7. Slide 7: R&D Process

    R&D Process Analysis, mathematical modeling, predictions Lab studies, Computational validation, Manual proof

  8. Slide 8: Genomic Infrastructure

    = Genomic Infrastructure

  9. Slide 9: The LEADS Process

    The LEADS Process • Computational biology platform since 1997 • Accurate modeling of transcriptome for drug discovery • In-silico process, wet validation • Used internally and by, among others: • Unique modeling of biological phenomena

  10. Slide 10: Compugen 1997: Alternative Splicing - One Gene Can Express Many Proteins

    Compugen 1997: Alternative Splicing One Gene Can Express Many Proteins Genome Res. July 2002 Science. May 2003 Genome Res. July 2003

  11. Slide 11: Compugen 1997: Alternative Splicing (cont.)

    Compugen 1997: Alternative Splicing One Gene Can Express Many Proteins (cont.) Trends in Genetics. February 2004 Molecular Cell. April 2004 Genome Res. Aug 2004

  12. Slide 12: Compugen 2001: Endogenous Antisense

    Compugen 2001: Endogenous Antisense Simultaneous Transcription on Both DNA Strands April 2003

  13. Slide 13: Compugen 2004: RNA Editing

    Compugen 2004: RNA Editing Thousands of A-to-I Sites August 2004 “Is abundant A-to-I RNA editing primate-specific?” Sergey, Yaron, Rotem, Gidi Rechavi, Erez L. and Dvir Trends in Genetics February 2005

  14. Slide 14: Discovery Engines: Therapeutic Proteins

    Discovery Engines: Therapeutic Proteins

  15. Slide 15: Potential Therapeutic Proteins

    Potential Therapeutic Proteins • CGEN-M3 (metastatic cancer) • CGEN-P4 (obesity and eating disorders) • CGEN-G11 (Type II diabetes and obesity) • CGEN-B2 (various cancers) • CGEN-40 (autoimmune diseases, cancer, organ transplantation, and inflammation) • CGEN-VEGF114 (cardiovascular disease) • CGEN-

  16. Slide 16: Therapeutic Protein Discovery Engines

    Therapeutic Protein Discovery Engines LEADS Engine monitored and improved

  17. Slide 17: Therapeutic Proteins: Selection Criteria

    Therapeutic Proteins: Selection Criteria • Splice variant of known therapeutic protein or drug target on the market or in advanced stages of development – Significant amounts of previously gathered relevant biological and medical information – Enables prediction of putative biological function and m

  18. Slide 18: Discovery Engines: Diagnostic Markers

    Discovery Engines: Diagnostic Markers

  19. Slide 19: Biomarker Candidates

    Biomarker Candidates • Immunoassays: – CGEN-B2 (breast cancer) – CGEN-BP1 (congestive heart failure) – CGEN-RP (breast and small cell lung carcinoma) – CGEN-S2 (ovarian cancer) • Nucleic acid testing: – CGEN-NL4 (small cell lung cancer) – CGEN-UH10 (lung and ovarian cancers) – CGEN-SIM2 (lung and ov

  20. Slide 20: Cancer Biomarker Engine

    Cancer Biomarker Engine Oligo LEADS Microarray Analysis design Identify candidates over- expressed in cancer Quantitative IP RT-PCR Initially validated novel markers

  21. Slide 21: Diagnostic Markers: Selection Criteria

    Diagnostic Markers: Selection Criteria • Differentiation between disease and healthy conditions – Predicted to be present in different quantities in diseased and healthy human tissues • Biological characteristics suitable for diagnostic detection – For example, secreted into the bloodstream (for det

  22. Slide 22: Business Model

    = Business Model

  23. Slide 23: Business Model

    Business Model • In-house development of therapeutic proteins – Sole and joint development efforts • Royalty bearing collaborations with respect to unique discovery capability – Out-licensing of diagnostic and therapeutic applications of specific discoveries – “Pipeline agreements” • Compugen uses d

  24. Slide 24: Agenda

    Agenda • Introduction to the Problem • The Compugen Approach – Small Molecule Drugs Financial • Business and Corporate Information model • Financial Status • A few Facts

  25. Slide 25: Corporate Information

    Corporate Information • Founded 1993 • IPO August 2000 (NASDAQ: CGEN) – TASE January 2002 • 130 employees – ~75% R&D, ~30% Ph.D. – Biology and chemistry wet labs • Facilities – Tel Aviv, Israel (Ltd. headquarters) – San Jose, California (Inc. headquarters) • Rockville, Maryland • Affiliates – Evogen

  26. Slide 26: Management Team

    Management Team • Martin Gerstel, Chairman of the Board • Mor Amitai, Ph.D., President & CEO • Eran Aharonson, VP Computational Life Sciences R&D • Nurit Benjamini, CFO • Erez Chimovits, President, Compugen USA, Inc. & EVP Commercial Operations • D’vorah Graeser, Ph.D., VP Intellectual Property • Sa

  27. Slide 27: Financial: Cash Flow and Shares

    Financial: Cash Flow and Shares (in millions) 2001 2002 2003 2004 Cash beginning of year $90.7 $78.5 $67.3 $60.5 Sources $15.3 $14.0 $12.2 $7.6 Uses ($27.5) ($25.2) ($19.0) ($19.7) Net “Cash Burn” ($12.2) ($11.2) ($6.8) ($12.1) Cash end of year $78.5 $67.3 $60.5 $48.4 Long-term debt none none none n

  28. Slide 28: Summary

    Summary • Unique predictive discovery capability integrating biology, chemistry, medicine, physics, math, and computer science • Deeper understandings of biological phenomena • Predicted models of transcriptome and proteome • Discovery engines built on the LEADS platform • Iterative improvements to

  29. Slide 29: www.cgen.com

    = wWwww.cgen.com «& —x — — — —— —_— —— ——_? ——— — ——— a —_ a———E —— 4 Se —_i ——_} — compugen

Compugen — Investor Presentation (May 2005) on 6ix